# A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 811 in Subjects With Systemic Lupus Erythematosus

> **NCT02291588** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 26 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** AMG 811
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02291588
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2010-03
- **Final completion:** 2010-06
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2014-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02291588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02291588, "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 811 in Subjects With Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT02291588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*